Get the Stockscreener App
99.91
2.67%
-2.76
Nuvalent Inc stock is traded at $99.91, with a volume of 68,783.
It is down -2.67% in the last 24 hours and down -0.96% over the past month.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
See More
Previous Close:
$102.67
Open:
$101.35
24h Volume:
68,783
Relative Volume:
0.13
Market Cap:
$7.86B
Revenue:
-
Net Income/Loss:
$-224.29M
P/E Ratio:
-25.62
EPS:
-3.9
Net Cash Flow:
$-185.06M
1W Performance:
-3.85%
1M Performance:
-0.96%
6M Performance:
+23.54%
1Y Performance:
+38.81%
1-Day Range:
$99.83
$103.83
1-Week Range:
$97.24
$104.11
52-Week Range:
$55.53
$113.02
Nuvalent Inc Stock (NUVL) Company Profile
Name
Nuvalent Inc
Sector
Industry
Phone
508-446-2272
Address
ONE BROADWAY, 14TH FLOOR, CAMBRIDGE
Compare NUVL vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NUVL
Nuvalent Inc
|
99.96 | 8.07B | 0 | -224.29M | -185.06M | -3.90 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.94 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
774.57 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
731.68 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
323.49 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
295.38 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Nuvalent Inc Stock (NUVL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-24-25 | Initiated | Truist | Buy |
| Nov-12-25 | Initiated | Canaccord Genuity | Buy |
| Oct-16-25 | Resumed | Stifel | Buy |
| Oct-15-25 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-04-25 | Resumed | Guggenheim | Buy |
| Sep-03-25 | Initiated | Raymond James | Outperform |
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| Mar-14-25 | Upgrade | UBS | Neutral → Buy |
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
| Oct-24-24 | Initiated | UBS | Neutral |
| Aug-29-24 | Initiated | Barclays | Overweight |
| Apr-17-24 | Initiated | Jefferies | Buy |
| Apr-01-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Feb-28-24 | Resumed | Guggenheim | Buy |
| Feb-23-24 | Initiated | Robert W. Baird | Outperform |
| Sep-27-23 | Initiated | Stifel | Buy |
| Aug-08-23 | Initiated | SVB Securities | Market Perform |
| Jul-24-23 | Initiated | Guggenheim | Buy |
| Jan-18-23 | Initiated | Wedbush | Outperform |
| Jun-24-22 | Initiated | BMO Capital Markets | Outperform |
View All
Nuvalent Inc Stock (NUVL) Latest News
HC Wainwright Brokers Lift Earnings Estimates for Nuvalent - MarketBeat
NUVL: Regulatory filings and commercial launches for ALK and ROS1 NSCLC therapies are on track for 2024 - TradingView
HC Wainwright Brokers Reduce Earnings Estimates for Nuvalent - MarketBeat
NUVLForm S-8Securities to be offered to employees in employee benefit plans - ADVFN Ltd
TD Asset Management Inc Increases Position in Nuvalent, Inc. $NUVL - MarketBeat
NUVL Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Nuvalent Insider Sold Shares Worth $566,788, According to a Recent SEC Filing - marketscreener.com
Nuvalent Executives Sell Shares Under Trading Plan - TradingView
Nuvalent (NUVL) CDO exercises options and sells 5,500 shares under 10b5-1 plan - Stock Titan
Nuvalent (NUVL) CLO sells 5,500 shares after option exercise - Stock Titan
Nuvalent, Inc. (NUVL) Stock Analysis: A Biotech With A Promising 40.78% Upside Potential - DirectorsTalk Interviews
UBS Adjusts Price Target on Nuvalent to $138 From $132, Maintains Buy Rating - marketscreener.com
Analysts Are Bullish on These Healthcare Stocks: Nuvalent (NUVL), Atai Beckley N.V. (ATAI) - The Globe and Mail
Biotech Fund Dumps $84 Million of Nuvalent With Stock Up 29% - AOL.com
Does Nuvalent (NUVL) Have the Potential to Rally 37.26% as Wall Street Analysts Expect? - Finviz
Does Nuvalent (NUVL) Have a Chance to Surge by 37.26% According to Wall Street Analysts? - Bitget
Nuvalent (NASDAQ:NUVL) Stock Price Expected to Rise, Cantor Fitzgerald Analyst Says - MarketBeat
Vanguard Group Inc. Raises Holdings in Nuvalent, Inc. $NUVL - MarketBeat
Decoding Nuvalent Inc (NUVL): A Strategic SWOT Insight - GuruFocus
Nuvalent reports Q4 loss, awaits FDA decision on lung cancer drug - Investing.com Australia
Nuvalent Outlines Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Fourth Quarter and Full Year 2025 Financial Results - The Malaysian Reserve
Nuvalent, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Nuvalent reports Q4 loss, awaits FDA decision on lung cancer drug By Investing.com - Investing.com South Africa
Nuvalent, Inc. SEC 10-K Report - TradingView
Nuvalent (NUVL) targets 2026 launches with ROS1 and ALK lung cancer drugs - Stock Titan
(NUVL) Risk Channels and Responsive Allocation - Stock Traders Daily
Nuvalent (NUVL) details 2025 results and key FDA milestones - Stock Titan
BRIEF-Nuvalent Q4 EPS USD -1.58 - TradingView
Biotech Fund Dumps $84 Million of Nuvalent With Stock Up 29% - The Motley Fool
Nuvalent, Inc. (NUVL) Stock Analysis: Exploring a 41.94% Potential Upside Amidst Strong Buy Ratings - DirectorsTalk Interviews
Nuvalent, Inc. (NASDAQ:NUVL) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Nuvalent, Inc. (NASDAQ:NUVL) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
Nuvalent (NUVL) Projected to Post Earnings on Thursday - MarketBeat
Trust linked to Nuvalent (NUVL) files Form 144 to sell 1,650 shares - Stock Titan
Bank Watch: Is Nuvalent Inc forming a bullish divergenceMarket Risk Analysis & Fast Gain Swing Alerts - baoquankhu1.vn
(NUVL) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Nuvalent Details FDA Timelines for ROS1, ALK Drugs as $1.4B Cash Fuels Global Launch Plans - MarketBeat
NUVL: Global launches of innovative ROS1 and ALK inhibitors drive growth and pipeline expansion - TradingView
Nuvalent honors women pioneers on Women in Science Day - Traders Union
Candriam S.C.A. Purchases 28,462 Shares of Nuvalent, Inc. $NUVL - MarketBeat
Assessing Nuvalent (NUVL) Valuation As DCF Signals Upside Versus Current Market Pricing - Yahoo Finance
US Stocks Recap: Is Nuvalent Inc forming a bullish divergenceJuly 2025 PostEarnings & Reliable Breakout Forecasts - baoquankhu1.vn
Nuvalent to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 – Company Announcement - Financial Times
Nuvalent to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 - Barchart.com
Liquidity Mapping Around (NUVL) Price Events - Stock Traders Daily
Nuvalent, Inc. (NUVL) Investor Outlook: Biotechnology Innovator with a 37.73% Potential Upside - DirectorsTalk Interviews
Nuvalent, Inc. (NUVL): Investor Outlook With A 33% Potential Upside - DirectorsTalk Interviews
Nuvalent, Inc. (NASDAQ:NUVL) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Aug Final Week: Is Nuvalent Inc benefiting from innovation trendsBreakout Watch & Long-Term Growth Plans - baoquankhu1.vn
Why (NUVL) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Insider Selling: Nuvalent (NASDAQ:NUVL) Insider Sells 14,300 Shares of Stock - MarketBeat
Nuvalent Inc Stock (NUVL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Nuvalent Inc Stock (NUVL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Noci Darlene | Chief Development Officer |
Feb 26 '26 |
Sale |
103.03 |
5,500 |
566,682 |
58,117 |
| Miller Deborah Ann | Chief Legal Officer |
Feb 26 '26 |
Option Exercise |
6.89 |
5,500 |
37,895 |
65,134 |
| Miller Deborah Ann | Chief Legal Officer |
Feb 26 '26 |
Sale |
103.05 |
5,500 |
566,788 |
59,634 |
0.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):